MedTrace Logo

Circulating Tumor Cells and Survival in Hormone Refractory Prostate Cancer (HRPC) Patients Receiving Chemotherapy

NCT00133900 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 276

Last updated 2009-07-28

No results posted yet for this study

Summary

This study enrolled men with prostate cancer who had failed hormone therapy (as shown by rising prostate-specific antigen \[PSA\] levels) and who were about to start a new line of chemotherapy. Blood was drawn prior to the patient receiving chemotherapy and then monthly thereafter for up to 18 months or until disease progression, whichever occurred first. The blood was tested to find circulating tumor cells (CTC) and to count them. The circulating tumor cell levels were studied in relation to the patient's overall survival. Serum was also collected for PSA testing, and additional blood samples were drawn to test for circulating endothelial cells and RNA was isolated for future gene expression testing.

Conditions

Interventions

PROCEDURE

Phlebotomy

Peripheral blood draws for evaluation of circulating tumor cells

Sponsors & Collaborators

  • Immunicon

    lead INDUSTRY

Principal Investigators

  • Ken Pienta, MD · University of Michigan

  • Derek Raghavan, M.D. · The Cleveland Clinic

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-12-31
Primary Completion
2009-02-28
Completion
2009-02-28

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00133900 on ClinicalTrials.gov